Data Insights

IC9 CAR.19 by Bellicum Pharmaceuticals for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval

IC9 CAR.19 is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Splenic Marginal Zone B-Cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - IC9 CAR.19 in Splenic Marginal Zone B-Cell Lymphoma

Data Insights

IC9 CAR.19 by Bellicum Pharmaceuticals for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

IC9 CAR.19 is under clinical development by Bellicum Pharmaceuticals and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell...

Likelihood of Approval and Phase Transition Success Rate Model - IC9 CAR.19 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

IC9 CAR.19 by Bellicum Pharmaceuticals for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

IC9 CAR.19 is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Extranodal Marginal Zone B-Cell Lymphoma...

Likelihood of Approval and Phase Transition Success Rate Model - IC9 CAR.19 in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)

Data Insights

IC9 CAR.19 by Bellicum Pharmaceuticals for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval

IC9 CAR.19 is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Nodal Marginal Zone B-Cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - IC9 CAR.19 in Nodal Marginal Zone B-Cell Lymphoma

Data Insights

IC9 CAR.19 by Bellicum Pharmaceuticals for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

IC9 CAR.19 is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - IC9 CAR.19 in Primary Mediastinal B-Cell Lymphoma

Data Insights

IC9 CAR.19 by Bellicum Pharmaceuticals for Follicular Lymphoma: Likelihood of Approval

IC9 CAR.19 is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Follicular Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - IC9 CAR.19 in Follicular Lymphoma

Data Insights

IC9 CAR.19 by Bellicum Pharmaceuticals for Mantle Cell Lymphoma: Likelihood of Approval

IC9 CAR.19 is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Mantle Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - IC9 CAR.19 in Mantle Cell Lymphoma

Data Insights

IC9 CAR.19 by Bellicum Pharmaceuticals for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

IC9 CAR.19 is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Diffuse Large B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - IC9 CAR.19 in Diffuse Large B-Cell Lymphoma